Trial Profile
A trial to assess changes in the T cell receptor (TCR) repertoire in peripheral venous blood of patients with multiple sclerosis (MS) treated with fingolimod
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Nov 2016
Price :
$35
*
At a glance
- Drugs Fingolimod (Primary)
- Indications Multiple sclerosis
- Focus Pharmacodynamics
- 06 May 2016 New trial record
- 21 Apr 2016 Results presented at the 68th Annual Meeting of the American Academy of Neurology